Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than ...

Monash University's Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median ...

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how the drug works.

June 24 (Reuters) - Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth up to ...

Genialis, the therapeutic intelligence company, today announced Genialis™ BioBridge to help pharmaceutical sponsors translate clinical results generated in Chinese patient populations into ...

Purdue researchers developed a mass spectrometry platform that accelerates cancer drug discovery by integrating synthesis, ...

Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug ...

The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases.

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from breaking when cells copy damaged genetic material, a discovery that could ...

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...